Alyssa Kate Mezochow, MD

Infectious Diseases
Accepting new patients
Sees patients age 18 and up
MacGregor Infection Medicine and Travel Program
View 1 additional location
Make an appointmentCall 800-789-7366
Headshot of Alyssa Kate Mezochow, MD
Penn Medicine Provider

About me

  • Instructor A of Medicine (Infectious Diseases)

My education and training

  • Medical School: Drexel University College of Medicine
  • Residency: Hospital of the University of Pennsylvania
  • Fellowship: Hospital of the University of Pennsylvania

Spoken languages

English
English

Insurance accepted

Please contact the practice and/or the member services department of your insurance company for specific details before receiving services. Providers may participate in some, but not all, products offered by a health plan; providers may also accept plans at some practice locations but not others.

Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
Dr. Mezochow is a Penn Medicine physician.

Qualifications and experience

Treatments and conditions

Research

Publications

He KD, Leonard SM, Mezochow A, Bermudez C, Courtwright A, Blumberg E. Impact of Donor Radiographic Pneumonia on Posttransplant Recipient Outcomes and Microbiology , Transpl Infect Dis: 2026

Mezochow AK, Clausen E, Whitaker K, Claridge T, Blumberg E, Courtwright AM. Letermovir should be first-line cytomegalovirus prophylaxis in lung transplant recipients , Am J Transplant: 2025

Torgersen J, Mezochow AK, Newcomb CW, Carbonari DM, Hennessy S, Rentsch CT, Park LS, Tate JP, Bräu N, Bhattacharya D, Lim JK, Mezzacappa C, Njei B, Roy JA, Taddei TH, Justice AC, Lo Re V 3rd. Severe Acute Liver Injury After Hepatotoxic Medication Initiation in Real-World Data , JAMA Intern Med, 184: 2024,943-952

Mezochow AK, He KD, Whitaker K, Blumberg E, Crespo MM, Courtwright A. Letermovir use for cytomegalovirus prophylaxis following lung transplantation: A single-center review , JHLT Open, 6: 2024,100149

Lo Re V 3rd, Newcomb CW, Carbonari DM, Mezochow AK, Hennessy S, Rentsch CT, Park LS, Tate JP, Bräu N, Bhattacharya D, Lim JK, Mezzacappa C, Njei B, Roy JA, Taddei TH, Justice AC, Torgersen J. Hepatotoxicity Score: A New Method to Adjust for Use of Potentially Hepatotoxic Medications by Chronic Liver Disease Status , Pharmacoepidemiol Drug Saf: 2024

Mezochow AK, Schaubel DE, Peyster EG, Lewis JD, Goldberg DS, Bittermann T. Hospitalizations for opportunistic infections following transplantation and associated risk factors: A national cohort study of Medicare beneficiaries , Transpl Infect Dis: 2024

Mezochow AK, Anesi J, West S, Hasz R, Edwards J, Blumberg EA. COVID-19 in organ donors: An organ procurement organization perspective , Transpl Infect Dis: 2024

Mezochow A, Anesi JA. The intricate interplay of immunosuppression and outcomes following Gram-negative bloodstream infection in solid organ transplantation , Transpl Infect Dis: 2022

Mezochow AK, Abt PL, Bittermann T. Differences in Early Immunosuppressive Therapy Among Liver Retransplantation Recipients in a National Cohort , Transplantation, 105: 2021,1800-1807

Torgersen J, Newcomb CW, Carbonari DM, Rentsch CT, Park LS, Mezochow A, Mehta RL, Buchwalder L, Tate JP, Bräu N, Bhattacharya D, Lim JK, Taddei TH, Justice AC, Lo Re V 3rd. Protease inhibitor-based direct-acting antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation , J Hepatol: 2021

View all publications